Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Chesney J, Awasthi S, Curti B, Hutchins L, Linette G, Triozzi P, Tan MCB, Brown RE, Nemunaitis J, Whitman E, Windham C, Lutzky J, Downey GF, Batty N, Amatruda T.
Chesney J, et al. Among authors: brown re.
Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399.
Melanoma Res. 2018.
PMID: 29176501
Clinical Trial.